CLINICAL_TRIALS
trial_result
· 2012-09-28
Clinical Trial Update: Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery [Phase 2]
Summary
This update reports Phase 2 results for using sorafenib in combination with erlotinib to treat unresectable pancreatic cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-09-28